Epogin epoetin beta regulatory update

The Pharmaceutical Affairs Subcommittee of Japan's Ministry of Health, Labor, and Welfare (MHLW) recommended against expanding the indication for Epogin epoetin beta from Chugai to include chemotherapy-induced anemia in solid tumor patients who are not eligible for curative surgery. Chugai said it will consider its actions regarding the indication. The erythropoiesis-stimulating agent (ESA) already is approved to treat anemia associated with chronic kidney disease (CKD) and for use in autologous blood transfusions. ...